Oncology

Implementation of clinical pathways saved $15,013 in the total cost of care per patient over a year.

Insurers can engage the practices they work with by building a sense of trust and open communication with the providers, according to Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

A new clinical pathways program at the Cancer Treatment Centers of America will help inform treatment by seamlessly integrating into the physician’s electronic health record.

Hospitals don't always adequately prepare patients for the reality of cancer treatment and all the ways it might affect someone's life, explained Melissa Thompson, MBA, healthcare strategist, patient, and self-advocate.

This week, the top news in managed care included President Donald Trump's first address to Congress, which included guiding principles for replacing the Affordable Care Act, a leaked version of the House GOP's own draft for healthcare reform, and a study finds a concerning trend in colorectal cancer rates among young adults.

While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

A key takeaway from a panel discussion at the Patient Access Network Foundation’s second cost-sharing roundtable was the need for educating stakeholders.

The incidence of colorectal cancer continues to decline for older Americans, but researchers have noticed a significant uptick in prevalence among young adults.

The Oncology Care Model (OCM) can challenge providers who are overwhelmed by the wide scope of data involved, according to Barry Russo, CEO of The Center for Cancer & Blood Disorders. He explained the importance of educating staff, physicians, and patients to help ease the journey towards any new model.

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

Expanding a health system pharmacy’s operations to include specialty drugs, namely oral oncology agents, improved patient care by reducing errors and saving costs.

A new grant aims to gather data on thousands of African American cancer survivors to understand factors that influence disease progression, recurrence, mortality, and quality of life.

A recent cost-effectiveness analysis of 4 colorectal cancer screening initiatives found that some strategies may be more valuable than others in reducing screening disparities.

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

Using body composition metrics to guide the dose in patients receiving anthracyclines-taxane—based chemotherapy for breast cancer can reduce treatment-related toxicity.

Presenters and panelists at the 5th annual Patient-Centered Oncology Care meeting provide their key takeaways.

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.

Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.

The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncologyâ„¢, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.

At the 5th annual Patient-Centered Oncology Care® meeting, stakeholders shared their views on how bundled payments, clinical pathways, and other value-based approaches can be implemented in cancer care while ensuring adequate care quality.

Panelists from diverse vantage points in the cancer care landscape discussed the effects of cost sharing on patients in a discussion at the 5th annual Patient-Centered Oncology Care® meeting.